Summary of Capricor Therapeutics, Inc. Q4 2025 Earnings Call

1Key Financial Results and Metrics:

Cash Position: As of December 31, 2025, Capricor reported cash and marketable securities totaling approximately $318 million, a significant increase from $151.5 million in the previous year.

Revenue: The company reported no revenue for 2025, down from approximately $11.1 million in 2024, primarily due to the completion of prior revenue recognition from a distribution agreement.

Operating Expenses: Total operating expenses rose to approximately $29.2 million for Q4 2025 and approximately $108.1 million for the full year, compared to $18.8 million and $64.8 million in 2024, respectively. The increase is attributed to investments in clinical, regulatory, and manufacturing activities.

Net Loss: The net loss for 2025 was approximately $30.2 million for Q4 and $105 million for the full year, compared to $7.1 million and $40.5 million in 2024.

2Strategic Updates and Business Highlights:

Regulatory Milestone: The FDA accepted Capricor's response to a complete response letter (CRL) regarding the biologics license application (BLA) for deramycin, with a target action date set for August 22, 2026.

Clinical Trial Success: The HOPE-3 trial demonstrated significant efficacy in treating Duchenne muscular dystrophy (DMD) cardiomyopathy, with key endpoints met, including a 91% slowing of disease progression in left ventricular ejection fraction.

Manufacturing Readiness: Capricor's San Diego facility has passed FDA pre-license inspection and is prepared to support an initial commercial launch, with plans for expansion to increase capacity from 250 to approximately 2,500 patients annually by late 2027.

Commercial Strategy: The company is focused on building a commercial infrastructure to support the launch of deramycin, including market access, reimbursement planning, and physician education.

3Forward Guidance and Outlook:

Capricor expects its current cash position to fund operations into 2027, excluding potential product revenues and the monetization of a priority review voucher (PRV) upon approval.

The company is preparing for a potential commercial launch of deramycin, anticipating strong demand given the unmet needs in the DMD community.

4Bad News, Challenges, or Points of Concern:

Revenue Decline: The complete absence of revenue in 2025 raises concerns about the company's financial sustainability until product approval and commercialization.

Increased Operating Losses: The significant increase in net losses may raise questions about the company's ability to manage expenses effectively as it prepares for commercialization.

Regulatory Risks: While the FDA has not indicated any review issues, the potential for unexpected regulatory challenges remains a concern as the company navigates the BLA review process.

5Notable Q&A Insights:

Advisory Committee (AdCom) Expectations: CEO Linda Marbán indicated uncertainty regarding the likelihood of an AdCom meeting but expressed confidence in the strength of the HOPE-3 data.

Labeling Discussions: There is anticipation that the FDA may consider both cardiomyopathy and skeletal muscle aspects in the labeling discussions, although no formal discussions have occurred yet.

Market Feedback: Feedback from the recent Muscular Dystrophy Association conference indicated increased confidence among physicians regarding deramycin, with many expressing eagerness to prescribe the therapy.

Future Manufacturing Plans: Capricor is actively planning to expand manufacturing capabilities to meet the anticipated demand for deramycin post-approval. Overall, Capricor Therapeutics is positioned at a critical juncture with promising clinical data and a strong financial position, but it faces challenges related to revenue generation and regulatory uncertainties as it approaches potential product approval.